Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article

This study has been completed.
Sponsor:
Information provided by:
Philip Morris Products S.A.
ClinicalTrials.gov Identifier:
NCT00812279
First received: December 19, 2008
Last updated: March 5, 2009
Last verified: March 2009

December 19, 2008
March 5, 2009
November 2008
February 2009   (final data collection date for primary outcome measure)
To demonstrate a reduction in the three primary biomarkers of exposure: Carboxyhaemoglobin concentration in blood, Urinary excretion of S-phenylmercapturic acid and urinary excretion of NNAL and NNAL-glucuronides (total NNAL) [ Time Frame: 5 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00812279 on ClinicalTrials.gov Archive Site
  • To explore changes from baseline COHb, S-PMA, and total NNAL in the three study arms in the course of the study [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To explore changes from baseline in the three study arms with regard to urinary excretion of biomarkers of exposure to several other smoke constituents. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To assess urinary excretion of nicotine and its five major nicotine metabolites in the three study arms [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To assess nicotine and cotinine concentrations in plasma in the three study arms To compare levels of all biomarkers of exposure in the SMAR arm to those in the smoking cessation (SC) arm [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To assess the mutagenicity potential in urine at the end of the study in the three study arms [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]
  • To monitor blood pressure, pulse rate, electrocardiogram, clinical laboratory parameters (standard clinical biochemistry, standard haematology and urine analysis), and adverse events [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]
  • To investigate craving and withdrawal symptoms as well as pulmonary symptoms in all three study arms by means of questionnaires [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • To investigate change in cytochrome P450 1A2 (CYP1A2) activity from D0 to D5 in the three study arms [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]
  • To assess and compare human smoking topography (HST) in smokers before and after switching to SMAR [ Time Frame: 5 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article
A Controlled, Randomised, Open-Label, 3-Arm Parallel Single-Centre Confinement Study to Investigate Exposure to Selected Smoke Constituents in Smokers Switching From Conventional Cigarettes to SMAR Cigarettes for 5 Days

The overall purpose of this clinical study conducted in confinement under well-defined conditions is to obtain initial data on the levels of human body exposure to selected smoked constituents of the SMAR cigarette.

The main objective of this study is to compare the biomarkers of exposure to cigarette smoke constituents in smokers switching to SMAR and to biomarkers in smokers of conventional cigarettes (CC). The biomarkers of exposure will be measured in blood and urine samples collected from the subjects. Moreover, the biomarkers in subjects smoking conventional or SMAR cigarettes will be compared with those biomarkers in smokers who stop smoking for 5 days. The short term safety of this new product will also be evaluated.

This is a controlled, randomised, open-label, 3-arm parallel single centre confinement study to investigate exposure to selected smoke constituents in smokers switching from CC to SMAR for 5 days.

112 eligible subjects will be randomised to the 3 study arms: SMAR, conventional cigarettes (CC) and smoking cessation (SC) in a 2:1:1 ratio.

Following the screening visit (within 4 weeks prior to the day of admission), the study will be run over an 8-day period in a confined environment, consisting of the admission day (D-2), a 2-day baseline period (D-1 and D0), and a 5-day exposure period (D1 to D5). Subjects will be discharged in the morning of D6. From the discharge of the subject, a 7-day safety follow-up period will be carried out (until D13).

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Smoking
  • Other: Distillation based smoking article (SMAR cigarette)
    Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
  • Other: conventional cigarette
    Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
  • Other: smoking cessation
    Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
  • Experimental: 1. SMAR
    Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times.
    Intervention: Other: Distillation based smoking article (SMAR cigarette)
  • Active Comparator: 2 Conventional cigarette (CC)
    Subjects will be allowed to smoke without any limit on consumption during the designated smoking times.
    Intervention: Other: conventional cigarette
  • Active Comparator: 3. smoking cessation (SC)
    Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
    Intervention: Other: smoking cessation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
112
February 2009
February 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Caucasian adult smokers (male and female), with acceptable health conditions, aged from 23 to 55 years who usually smoke 10 to 30 non-mentholated conventional cigarettes (with a maximum ISO tar yield of 10 mg) per day, for at least the last 5 consecutive years, will be enrolled in this study.

Exclusion Criteria:

  • women of childbearing potential must be excluded if:Subject is pregnant (does not have negative pregnancy tests at screening and at D-2) or breastfeeding/ subject does not agree to use an acceptable method of effective contraception: intrauterine device, intrauterine system, established use of oral/injectable/implantable/ transdermal hormonal methods, barrier methods of contraception (condoms, occlusive caps) with spermicidal foam/gel/film/suppository, vasectomised partner or true abstinence (periodic abstinence and withdrawal are not effective methods) until the end of the safety follow-up period.
Both
23 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Poland
 
NCT00812279
YVD-CS01-EU
No
John L. Magnette - Head Clinical Assessment, Philip Morris Products SA
Philip Morris Products S.A.
Not Provided
Principal Investigator: Katarzyna Jarus-Dziedzic, MD MTZ Clinical Research Inc (Warsaw, Poland)
Philip Morris Products S.A.
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP